Treatment of recurrent gastrointestinal haemorrhage in a patient with von Willebrand's disease with octreotide LAR and propranolol

Krikis, Napoleon

doi:10.1136/gut.2004.049031

Cited by 13 publications

(8 citation statements)

References 7 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No larger series but numerous case reports have been published so far 17 18. In paediatric liver disease with portal hypertension leading to acute haemorrhage, however, octreotide treatment was shown to be safe and effective 8 19.…”

Section: Discussionmentioning

confidence: 99%

Long-time octreotide in an adolescent with severe haemorrhagic gastrointestinal vascular malformation

Classen

Haffner²,

Hauenstein³

et al. 2011

Case Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Long-time octreotide in an adolescent with severe haemorrhagic gastrointestinal vascular malformation

Classen

Haffner²,

Hauenstein³

et al. 2011

Case Reports

View full text Add to dashboard Cite

“…A loss of multimers was present in all continuous flow LVAD patients after implant, whereas their plasma levels were normal in the pulsatile LVAD group. GIB could be due to coagulation problems, but also due to angiodysplasia, which has been documented in patients with congenital or acquired vWF deficiency [42][43][44][45], with normal pulsatility. Moreover, vWF deficiency promotes angiogenesis [46,47].…”

Section: Gastrointestinal Bleeding and Coagulation Disturbancesmentioning

confidence: 97%

Debate

Schima

Dimitrov²,

Zimpfer³

2016

Current Opinion in Cardiology

View full text Add to dashboard Cite

show abstract

“…El propósito de este trabajo, por tanto, es acercar al clínico el mayor número de posibilidades terapéuticas para afrontar el gran reto que casi siempre supone el tratamiento farmacológico de los pacientes con HDOO, muchos de ellos de edad avanzada y comorbilidad asociada e incluso con necesidad de tratamiento antiagregante o anticoagulante que predispone a una mayor riesgo hemorrágico. Algunos de estos fármacos han sido utilizados como terapia combinada en la literatura (7,8).…”

Section: Introductionunclassified

Avances en el tratamiento farmacológico de la hemorragia digestiva de origen oscuro

Infante

Gallardo

Bermejo

2007

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

The development of capsule endoscopy and double-balloon enteroscopy has increased diagnostic and therapeutic rates in obscure gastrointestinal hemorrhage, where angiodysplasia of the small bowel is the most frequent cause. Nevertheless, almost 25-40% of patients who are not candidates or do not respond to endoscopic, angiographic, or surgical management may be at high risk of rebleeding, and therefore lack a clearly effective medical therapy. The utility of hormonal therapy remains unclear and is burdened by adverse effects. Subcutaneous octreotide usually controls bleeding but does not seem adequate for maintenance therapy. Non-selective beta-blockers alone or in combination with other treatments, as in the prophylaxis of portal hypertension variceal bleeding, may be helpful. Recently, octreotide LAR, a depot formulation administered once a month intramuscularly, and oral thalidomide, a powerful inhibitor of angiogenesis, have demonstrated their effectiveness and safety for long-term therapy in anecdotal case reports and deserve further investigation.

show abstract

Treatment of recurrent gastrointestinal haemorrhage in a patient with von Willebrand's disease with octreotide LAR and propranolol

Cited by 13 publications

References 7 publications

Long-time octreotide in an adolescent with severe haemorrhagic gastrointestinal vascular malformation

Long-time octreotide in an adolescent with severe haemorrhagic gastrointestinal vascular malformation

Debate

Avances en el tratamiento farmacológico de la hemorragia digestiva de origen oscuro

Contact Info

Product

Resources

About